Our Specialists for Spinal Metastasis and Metastatic Epidural Spinal Cord Compression
Spinal metastasis sits at the intersection of cancer care, spine surgery, and radiation oncology. At UChicago, your case is reviewed by a team that treats these tumors every week and uses modern tools like separation surgery and spine stereotactic body radiation therapy (SBRT).
Dr. Bydon is the Chair of Neurological Surgery at UChicago and a pioneer in minimally invasive and robotic spine surgery. He led the stem cell trial, the first-in-human stem cell therapy for spinal cord injury, and holds 12 medical device patents with over 600 peer-reviewed publications. He was recruited to UChicago from Mayo Clinic. Dr. Bydon's research has directly shaped how spinal metastasis patients are triaged: in a Journal of Clinical Neuroscience analysis of national data, he and colleagues showed that higher surgeon and hospital volume significantly lower the odds of complications and non-routine discharge after spine metastasis surgery (J Clin Neurosci, 2016). For many patients with metastatic epidural cord compression at UChicago, he is likely your surgeon.
Dr. Witham is Section Chief of Spine Surgery at UChicago and a pioneer in augmented reality-guided spine surgery. In 2020 he performed the first FDA-cleared AR-guided spine surgery on a living patient using the xvision system, and he has published extensively on AR-assisted pedicle screw placement. He came to UChicago from Johns Hopkins, where he was Professor of Neurological Surgery and Orthopaedic Surgery and served as co-program director of the neurosurgery residency. Dr. Witham is a fellowship-trained spine oncology surgeon whose Johns Hopkins group helped define the evidence base for minimally invasive approaches to vertebral metastases and the role of separation surgery combined with stereotactic radiation. He brings that same playbook - small incisions, spine stabilization, and rapid handoff to SBRT - to UChicago patients with MESCC.
Dr. Yamini is a brain tumor surgeon and scientist who serves as Vice Chair for Academic Affairs and Director of Neurosurgical Oncology at UChicago. In the operating room, he uses advanced imaging and navigation tools for stereotactic biopsy, laser ablation, and image-guided maximal resection. In his lab, he runs NIH-funded research into why some tumors resist treatment and into biodegradable nanoparticle vectors that deliver drugs directly to CNS tumors. Dr. Yamini is Director of Neurosurgical Oncology at UChicago and sees spine tumor patients in a combined clinic with medical and radiation oncology, so treatment decisions for spinal metastasis are made by the whole team in the same visit rather than in sequence. His laboratory work on how tumors resist treatment feeds directly into how aggressively a given metastasis is treated.
What Is Spinal Metastasis?
A spinal metastasis is a deposit of cancer that has traveled from somewhere else in the body - most often the breast, lung, prostate, kidney, or thyroid - and lodged in the bones of the spine. The spine is the most common site of bone metastasis, and roughly 30 to 40 percent of people with advanced cancer will develop one during the course of their illness.
Most spinal metastases start inside the vertebral body (the block-shaped part of the bone in front of the spinal cord). As the tumor grows, it can do three things that matter clinically: it can weaken the bone until it collapses, it can push on the spinal cord or nerve roots, and it can cause pain that does not respond to normal painkillers.
When tumor from the spine grows into the spinal canal and presses on the cord, doctors call it metastatic epidural spinal cord compression, or MESCC. This is the version of spinal metastasis that becomes a surgical emergency. Without prompt treatment, MESCC can take someone from walking to paralyzed in a matter of days.
The good news: spinal metastasis is very treatable. The goals are clear - control pain, keep you walking, keep your spine stable, and preserve your quality of life while your oncology team treats the underlying cancer.
At a Glance
- Spinal metastasis means cancer has spread to the bones of your spine; it is the most common tumor problem spine surgeons treat
- New or worsening leg weakness, numbness, or loss of bladder control is a medical emergency - go to an emergency room
- The landmark Patchell trial proved that surgery followed by radiation keeps more patients walking than radiation alone
- Modern care uses a decision tool called NOMS - Neurologic, Oncologic, Mechanical, and Systemic - to match treatment to you
- For many patients, a shorter "separation surgery" plus focused radiation (SBRT) now replaces large tumor-removal operations
Have imaging or a diagnosis already?
We'll have a specialist review your MRI and records — often within 24 hours.
What Does It Feel Like?
Most people with spinal metastasis notice back or neck pain first, often weeks or months before anything else. The pain has a few giveaway features that separate it from ordinary mechanical back pain:
Warning signs of cancer-related spine pain
- Pain that is worse at night or wakes you from sleep
- Pain that gets worse when you lie down flat, and better when you sit up or stand
- New back or neck pain in someone with a known cancer history
- A deep, relentless ache that does not track with activity
- A sudden sharp pain when you cough, sneeze, or roll over (a sign the bone may have fractured)
Signs of spinal cord compression - seek emergency care
If the tumor begins pressing on the spinal cord itself, the symptoms shift from pain to neurologic problems. These signs mean you should go to an emergency room immediately:
- New weakness in your legs or difficulty standing up from a chair
- Numbness or tingling that starts in the feet and climbs up
- A "band" of numbness around your chest or abdomen
- Loss of control of your bladder or bowels, or a new feeling of not being able to empty your bladder
- Numbness in the saddle area (inner thighs, groin)
- An unsteady or wide-based walk
The single most important prognostic factor for walking again is your neurologic status when treatment starts. Patients who are still walking when they reach the operating room are overwhelmingly likely to stay walking. Patients who have already become paralyzed rarely recover. That is why the urgency matters.
How Is It Diagnosed?
If your team suspects spinal metastasis, the workup happens quickly and in a predictable order.
MRI of the whole spine
MRI with and without contrast is the single best test. It shows where the tumor is, how much of the bone is involved, whether the spinal cord is being compressed, and whether there are other lesions higher or lower in the spine. We almost always image the entire spine, because metastases often show up at more than one level and a second, unsuspected lesion can change the plan.
The Bilsky ESCC grade
On the axial MRI images, your team grades how much the tumor is pressing on the spinal cord using the Bilsky Epidural Spinal Cord Compression (ESCC) scale, a 6-point scoring system. Grades 0 to 1 mean bone-only or minimal epidural disease; grade 2 means the tumor is touching the cord; grade 3 means the cord is compressed with no visible cerebrospinal fluid around it. Bilsky grade 2 and 3 lesions are the ones that typically need surgical decompression before radiation.
CT scan
CT gives the best look at the bone itself - how much of the vertebra is destroyed, whether there is a fracture, and whether the spine is still mechanically stable. CT also guides screw placement if surgery is needed.
Biopsy - sometimes
If you have a known cancer and the MRI looks classic, a biopsy may not be necessary. But if this is your first hint of cancer, or if your oncologist needs updated molecular information, a CT-guided needle biopsy of the spine lesion is usually the next step.
Staging the rest of the body
Finally, we need to know what else is going on. A PET/CT, CT of the chest/abdomen/pelvis, or bone scan gives the oncology team the full picture so the treatment plan can account for systemic disease - not just the spine lesion in front of us.
Deciding on Treatment: the NOMS Framework
No two spinal metastases are the same, and the right treatment depends on more than just the MRI. The spine oncology world uses a decision tool called NOMS, developed at Memorial Sloan Kettering by Bilsky and Laufer, to match each patient to the right combination of radiation, surgery, and systemic therapy. The four pillars are:
N - Neurologic
How much is the tumor pressing on the spinal cord, and is there a neurologic deficit? This is driven by the Bilsky ESCC grade. Low-grade compression can often be treated with radiation alone. High-grade compression with a deficit typically needs surgical decompression first.
O - Oncologic
How radiation-sensitive is your specific cancer? Some tumors, like lymphoma, multiple myeloma, and small cell lung cancer, essentially melt away with radiation. Others, like renal cell carcinoma, melanoma, and sarcoma, are classically "radioresistant" to conventional radiation - and for those, we rely on spine stereotactic body radiation therapy (SBRT), which delivers a much higher, focused dose that overcomes the usual resistance.
M - Mechanical
Is your spine actually stable? This is scored using the Spinal Instability Neoplastic Score (SINS), a 0 to 18 point scale developed by the Spine Oncology Study Group. It looks at the location of the tumor, the type of bone destruction, how the bone aligns, whether the vertebra has collapsed, and whether the back elements are involved. A score of 0 to 6 is stable; 7 to 12 is potentially unstable; 13 to 18 is frankly unstable and usually needs a stabilization procedure - even if the tumor itself is radiation-sensitive.
S - Systemic
How is the rest of your cancer behaving, and can you tolerate surgery? Someone with aggressive widespread disease, a short life expectancy, or poor performance status may be better served by radiation, a quick cement procedure (kyphoplasty), or focused palliative care instead of a major operation.
The NOMS framework is not a formula - it is a shared language your neurosurgeon, radiation oncologist, and medical oncologist use to make the call together.
How Is It Treated?
Emergency decompression - the Patchell trial
For patients with MESCC and a neurologic deficit, the single most important study in the field is the Patchell randomized trial, published in The Lancet in 2005. Patchell and colleagues randomly assigned 101 patients with spinal cord compression from cancer to either radiation alone or direct surgical decompression followed by radiation. The surgery arm crushed the radiation-only arm on every endpoint that matters: 84 percent of surgical patients were walking after treatment versus 57 percent of those given radiation alone, and the surgical patients kept their ability to walk more than three times longer. The trial ended early because the difference was so clear.
Patchell reset the standard of care. For the right patient - a neurologic deficit, a reasonable prognosis, and a tumor that is not exquisitely radiation-sensitive - surgery first, then radiation is the answer.
Separation surgery plus SBRT
The surgical goals have since evolved. In the old days, spine surgeons tried to remove as much tumor as possible, which meant long operations and long recoveries. Today, most MESCC cases at a high-volume center are treated with separation surgery: a shorter, more targeted operation that removes just enough tumor to create a 2 to 3 millimeter gap between the spinal cord and any remaining disease, stabilizes the spine with screws and rods, and then hands off to the radiation oncologist for spine SBRT.
The radiation then does the tumor-killing work. Because there is now a safe distance between the cord and the target, the radiation team can deliver a much higher dose - usually 24 to 30 Gy in 1 to 3 fractions. This combination has produced local control rates around 90 percent at one year, even for tumor types that used to be considered radioresistant. It is a dramatically less invasive operation with better cancer outcomes than what we used to do.
Spine SBRT without surgery
Not every spinal metastasis needs surgery. For patients with low-grade or no cord compression, a stable spine, and a radioresistant tumor, spine SBRT alone is often the best choice. The CCTG SC.24 randomized trial (Sahgal et al., Lancet Oncology, 2021) showed that SBRT delivered 24 Gy in two fractions produced a complete pain response at 3 months in 35 percent of patients - compared with 14 percent for standard radiation. SBRT also gives more durable tumor control.
Vertebroplasty and kyphoplasty
If the tumor has caused a painful vertebral compression fracture but the spinal cord is not being squeezed, we can often skip the operating room entirely. Vertebroplasty and kyphoplasty are minimally invasive procedures in which a thin needle is placed through a small skin incision into the collapsed vertebra, and medical-grade bone cement is injected to stabilize it. In kyphoplasty, a small balloon is first inflated to try to restore the height of the bone before the cement goes in.
The Cancer Patient Fracture Evaluation (CAFE) trial (Berenson et al., Lancet Oncology, 2011) randomized 134 cancer patients with painful vertebral compression fractures to kyphoplasty versus standard care and showed a dramatic improvement in disability and pain scores in the kyphoplasty group within one month. These procedures can often be done as same-day outpatient treatments.
Minimally invasive stabilization
When the spine is mechanically unstable but the tumor itself does not need to be removed through an open operation, percutaneous pedicle screw stabilization is an option: long screws are placed through small skin incisions, sometimes paired with kyphoplasty, to stabilize the painful segment with very little blood loss and a much faster recovery. This is especially useful for patients with advanced systemic disease who cannot tolerate a major surgery.
Systemic therapy and bone-targeted agents
Surgery and radiation fix the spine - but they do not treat the underlying cancer. Your oncology team will continue or adjust your chemotherapy, targeted therapy, immunotherapy, or hormonal therapy based on the tumor type. Bone-targeted agents like zoledronic acid or denosumab reduce the risk of future fractures and other skeletal events and are part of nearly every modern spinal metastasis plan.
Considering surgery or planning a second opinion?
Our multidisciplinary team reviews complex cases together. You'll get a coordinated plan, not one opinion.
What Are the Outcomes?
The honest truth about spinal metastasis is that the outcomes depend on two different clocks. The first clock is the spine clock: can we keep you walking, pain-free, and out of a back brace? On that clock, modern care is remarkably good. The second clock is the cancer clock: how long the underlying disease lets you live. That varies dramatically by tumor type.
Ambulation
The Patchell trial established that for patients treated with surgery plus radiation, about 84 percent are walking after treatment, compared with 57 percent for radiation alone. Among patients who arrive already walking, over 90 percent stay walking with surgical decompression. Among patients who arrive paraplegic, about 1 in 3 regain the ability to walk with urgent surgery - which is why any new weakness is treated as an emergency.
Local tumor control
With modern spine SBRT, 1-year local control rates are in the 85-90 percent range, even for tumors previously considered radioresistant like renal cell carcinoma, melanoma, and sarcoma. Gerszten's single-institution series of 500 spine lesions and Yamada's high-dose single-fraction series both reported local control near 90 percent across a wide variety of tumor histologies.
Survival by tumor type
Survival after treatment of a spinal metastasis is driven by the primary cancer - not by the spine lesion itself. Rough median survival numbers from large contemporary series:
| Primary cancer | Typical median survival after spine treatment | What to know |
|---|---|---|
| Breast cancer | 24-36 months | Often responsive to hormonal or targeted therapy; many long survivors |
| Prostate cancer | 18-30 months | Usually radiation-sensitive; hormone therapy central |
| Renal cell carcinoma | 12-24 months | Radioresistant - SBRT or surgery preferred |
| Thyroid cancer | 24-48+ months | Often slow-growing; aggressive local treatment worthwhile |
| Non-small cell lung cancer | 6-12 months | Highly variable with modern targeted/immunotherapy |
| Multiple myeloma / lymphoma | 36+ months | Extremely radiation-sensitive; often no surgery needed |
These are averages from older published series - actual results for any individual patient are now better in many cases thanks to modern systemic therapy. The goal of spine care in 2026 is not just a few extra months of life. It is to keep you walking, pain-free, and independent for as many of those months as possible.
References
Have Questions About Spinal Metastasis?
Our team is here to review your case, discuss your options, and help you take the next step.
Schedule: (773) 702-2123